December 17, 2009 – Racial and ethnic disparities in cancer survival are greatest for cancers that can be detected early and treated successfully, including breast and prostate cancer, according to a study by researchers at Columbia University’s Mailman School of Public Health and Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital. Disparities are small or nonexistent for cancers that have more limited early detection and treatment options, such as pancreatic and lung cancer.
The findings, published in the October 2009 issue of Cancer Epidemiology, Biomarkers, and Prevention, highlight the need to develop specific health policies and interventions to address social disparities.
Although prior studies have focused on factors that contribute to disparities in specific cancers, the Mailman School researchers’ goal in this study was to understand why racial/ethnic disparities emerge in some cancers but not others. The study used data from more than 580,000 cancer cases in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registries to compare racial/ethnic differences in survival across a spectrum of cancers, classified according to their five-year relative survival rates as a measure of how amenable each cancer is to medical interventions. The authors hypothesized that racial/ethnic disparities increase as medical interventions improve overall survival because individuals with more socioeconomic resources are in a better position to exploit medical advances to protect their health.
The results found that, as compared with whites, substantial survival disparities existed in more treatable cancers in African-Americans, American Indians/Alaska Natives, Hispanics, and several subgroups of the Asian/Pacific Islander population.
“Our findings may seem counterintuitive at first since medical advances in the last few decades have resulted in substantial improvements in cancer survival for most racial/ethnic population groups. However, this enhanced capacity to successfully treat certain cancers, when combined with the social disadvantage faced by many minorities, can lead to greater relative differences in cancer survival by race and ethnicity,” said Parisa Tehranifar, DrPH, assistant professor of Epidemiology, a member of the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital and the Mailman School of Public Health’s Center for the Study of Social Inequalities in Health and lead author of the paper.
“If we are correct in our interpretation that these disparities emerge as a result of greater utilization of available interventions by socially advantaged groups, it follows that interventions that are easy to access and use, and do not rely heavily on personal resources such as educational and income levels, may have the greatest potential for reducing cancer and other health disparities,” noted Dr. Tehranifar.
“Our cancer prevention and treatment efforts should continue to advance our public health and medical capacity for lowering the burden of cancer and mortality. However, we must also pay close attention to how the benefits of our medical advances are distributed in the population, and implement specific strategies that can reduce cancer disparities,” said Mary Beth Terry, PhD, associate professor of Epidemiology, a co-leader of the Cancer Epidemiology Program at the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital, and senior author of the paper.
Supported by a Lance Armstrong Foundation Young Investigator Award and a postdoctoral fellowship from the National Cancer Institute, the research was done in collaboration with: Dr. Alfred I. Neugut, MD, PhD; Myron Studner Professor of Cancer Research in the Department of Medicine and professor of Epidemiology, and leader of the Prevention, Control & Disparities Program at the Herbert Irving Comprehensive Cancer Center (HICCC) at Columbia University Medical Center/NewYork-Presbyterian Hospital; Jo C. Phelan, PhD, associate professor of Sociomedical Sciences; and Bruce G. Link, PhD, professor of Sociomedical Sciences and Epidemiology. Drs. Phelan and Link are also co-directors of Mailman School’s Center for the Study of Social Inequalities and Health.
The only accredited school of public health in New York City and among the first in the nation, Columbia University Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting millions of people locally and globally. The Mailman School is the recipient of some of the largest government and private grants in Columbia University’s history. Its more than 1000 graduate students pursue master’s and doctoral degrees, and the School’s 300 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as infectious and chronic diseases, health promotion and disease prevention, environmental health, maternal and child health, health over the life course, health policy, and public health preparedness. www.mailman.columbia.edu
The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital encompasses pre-clinical and clinical research, treatment, prevention and education efforts in cancer. The Cancer Center was initially funded by the NCI in 1972 and became a National Cancer Institute (NCI)–designated comprehensive cancer center in 1979. The designation recognizes the Center’s collaborative environment and expertise in harnessing translational research to bridge scientific discovery to clinical delivery, with the ultimate goal of successfully introducing novel diagnostic, therapeutic and preventive approaches to cancer. www.hiccc.columbia.edu.